Community-acquired sepsis or septic shock in neonates and children younger than 2 months who do not have meningitis

For term and preterm neonates with late onset community-acquired sepsis or septic shock (occurring after 72 hours of birth) who do not have meningitis (ie excluded by lumbar puncture), and children younger than 2 months who have community-acquired sepsis or septic shock who do not have meningitis, as a 2-drug regimen, use:

1gentamicin intravenously; see Principles of aminoglycoside use for prescribing considerations and subsequent dosing gentamicin

term and preterm neonate: see Initial aminoglycoside dosage for treating infection in neonates for initial dose

child 1 to 2 months: 7 mg/kg for initial dose

OR

1tobramycin intravenously; see Principles of aminoglycoside use for prescribing considerations and subsequent dosing tobramycin

term and preterm neonate: see Initial aminoglycoside dosage for treating infection in neonates for initial dose

child 1 to 2 months: 7 mg/kg for initial dose

PLUS EITHER

1amoxicillin 50 mg/kg intravenously amoxicillin

neonate less than 7 days: 12-hourly

neonate 7 days or older: 8-hourly

child 1 to 2 months: 6-hourly

OR

1ampicillin 50 mg/kg intravenously ampicillin

neonate less than 7 days: 12-hourly

neonate 7 days or older: 8-hourly

child 1 to 2 months: 6-hourly.

In neonates and children suspected to have HSV infection, or neonates whose birthing parent had active genital HSV infection at birth, add aciclovir to the above regimens. Use:Australasian Society for Infections Diseases (ASID) 2022

aciclovir 20 mg/kg intravenously, 8-hourly1. aciclovir

For more information on the management of neonates suspected to have HSV infection, or whose birthing parent had active genital HSV infection at birth, see the Australasian Society for Infectious Diseases (ASID) Management of Perinatal Infections guidelines.

If HSV infection is confirmed, see Neonatal herpes simplex infection for subsequent management.

For neonates and children at increased risk of MRSA infection (eg exposed to a caregiver colonised with MRSA), add vancomycin to the above regimens. Use:

vancomycin intravenously; for initial dosing, see Intermittent vancomycin dosing in young infants. vancomycin

If intravenous (or intraosseous) access cannot be rapidly established (eg within 15 minutes), the initial dose of antimicrobial therapy can be administered intramuscularly. For neonates and children who do not have meningitis (ie excluded by lumbar puncture), as a 2-drug regimen, use:

1gentamicin intramuscularly; see Principles of aminoglycoside use for prescribing considerations and subsequent dosing gentamicin

term and preterm neonate: see Initial aminoglycoside dosage for treating infection in neonates for initial dose

child 1 to 2 months: 7 mg/kg for initial dose

OR

1tobramycin intramuscularly; see Principles of aminoglycoside use for prescribing considerations and subsequent dosing tobramycin

term and preterm neonate: see Initial aminoglycoside dosage for treating infection in neonates for initial dose

child 1 to 2 months: 7 mg/kg for initial dose

PLUS EITHER

1amoxicillin 50 mg/kg intramuscularly, as a single dose while establishing intravenous (or intraosseous) access amoxicillin

OR

1ampicillin 50 mg/kg intramuscularly, as a single dose while establishing intravenous (or intraosseous) access. ampicillin

Vancomycin and aciclovir cannot be administered intramuscularly. If the neonate or child is at increased risk of MRSA infection (eg exposed to a caregiver colonised with MRSA) or if HSV infection is suspected, seek expert advice.

Establish intravenous (or intraosseous) access before the next scheduled antimicrobial dose. There are few data on absorption and distribution of intramuscular antimicrobials in sepsis or septic shock.

1 In neonates younger than 30 weeks corrected gestational age (corrected gestational age = postnatal age [time since birth] – weeks of prematurity), consider 12-hourly dosing if HSV infection has not been confirmed.Return